<strong>ARVO</strong> 2013 Annual Meeting Abstracts by Scientific Section/Group - <strong>Cornea</strong>analyzed with image processing software. Epithelial migration rate(EMR, in µm/h) and estimated time of healing (ETH, in hours) werecalculated.Results: Density and length of subbasal nerves decreasedsignificantly after 1 month in dry eyes compared to control eyes.Subbasal nerves appeared less branched and the number of epithelialnerve terminals was significantly reduced. These effects were moreprominent 2 months after induction of eye dryness. 4-8 months aftertearing deficiency, density and length of subbasal corneal nerves hadrecovered values close to control, although nerve architecture was notfully normal. EMR was significantly decreased and ETH wassignificantly increased 1 and 6 months after surgery (Table 1),although at month 6th, ETH was partly recovered.Conclusions: The changes in corneal subbasal nerve architecture 1-2months after lacrimal gland removal suggest that nerve damagedevelops shortly after induction of reduced tearing, leading to aneurotrophic slowdown of epithelial wound healing. At longer times,regeneration of corneal nerves appears to restore in part the woundhealing capabilities of the normal corneal epithelium.Commercial Relationships: Kamila Mizerska, None; NicolasCuenca, Universidad de Alicante (P); Carolina Luna, None; SusanaQuirce, None; Laura Fernandez-Sanchez, None; Illes Kovacs,None; M Carmen Acosta, None; Carlos Belmonte, None; JuanaGallar, NoneSupport: SAF2011-22500, CSD2007-00023, IPT-2011-1110-900000 and BFU2008-04425, and in part by BFU2012-36845 andRETICS RD12/0034/0010 (Ministerio de Ciencia e Innovación,Spain, and FEDER, EU)Program Number: 4313 Poster Board Number: C0051Presentation Time: 8:30 AM - 10:15 AMIsolation and characterization of progenitor cells from intactrabbit lacrimal glandHong He 1 , Guoying Sun 1 , Hui Lin 1 , Marie A. Shatos 2 , Darlene A.Dartt 2 , Samuel C. Yiu 1, 3 . 1 Wilmer Eye Institute, Baltimore, MD;2 Shepens Eye Research Institute, Boston, MA; 3 King Khaled EyeSpecialist Hospital, Riyadh, Saudi Arabia.Purpose: Lacrimal gland dysfunction is believed to be the singlemost important factor resulting in aqueous-deficient dry eye.Regeneration of the lacrimal gland using progenitor cells maypotentially restore lacrimal gland function and therefore improve theocular surface health. Previous studies have documented the role ofprogenitor cells in the repair of murine lacrimal glands. Since rabbitis a promising animal model for further lacrimal gland study (due tobetter accessibility to its ocular surface), it is important to studywhether the progenitor cells also exist in rabbit LGs. The purpose ofthis study is to investigate the presence of progenitor cells in intactadult rabbit LGs, and if they could be isolated and expand in vitro.Methods: Frozen intact rabbit LG sections were made. While acinarand duct cells were identified by their respective cellularmorphology, myoepithelial cells were identified byimmunohistochemistry (IHC) using antibody against alpha-smoothmuscle actin (α-SMA). The presence of progenitor cells wasdetermined using IHC by exploring for the expression of selectedstem cell markers - △Np63, ABCG2, Pax6, vimentin. Immature cellswere isolated from LGs using enzyme digestion and mechanicalseparation and subsequently grown in keratinocyte growth medium(KGM) without fetal bovine serum. The expression of selected stemcell markers and α-SMA in immature cells from passage 0 (P0) topassage 2 (P2) was examined by immunocytochemistry (ICC).Results: In the intact adult rabbit LGs, some myoepithlial and ductcells expressed stem cell markers - △Np63, ABCG2, Pax6 andvimentin. Isolated immature cells were found to successfully passageand expand in serum-free KGM, and express stem cell markers -△Np63, ABCG2, Pax6 and vimentin - in a subpopulation from P0 toP2. In addition, some isolated immature cells expressing stem cellmarkers were also found to be labeled with α-SMA.Conclusions: We conclude that progenitor cells exist in intact adultrabbit LGs and can be isolated in vitro. Our results also indicate thatthe progenitor cells may not only be myoepithelial cells but also ductcells.Commercial Relationships: Hong He, None; Guoying Sun, None;Hui Lin, None; Marie A. Shatos, None; Darlene A. Dartt, None;Samuel C. Yiu, NoneProgram Number: 4314 Poster Board Number: C0052Presentation Time: 8:30 AM - 10:15 AMAlterations of Tear Functions and Ocular Surface EpithelialDifferentiation in the SOD-1 Knock- out MouseMURAT DOGRU 1, 2 , Takashi Kojima 2, 1 , Taeko Nagata 2, 1 , AyakoIgarashi 1, 2 , Kazunari Higa 1, 2 , Yoshiyuki Satake 1 , Seika Shimazaki 1 ,Shimizu Takahiko 3 , Kazuo Tsubota 2, 1 , Jun Shimazaki 1 .1 Ophthalmology, Tokyo Dental College, Ichikawa, Japan;2 Ophthalmology, Keio University School of Medicine, Tokyo, Japan;3 Institute of Aging, Chiba University School of Medicine, Chiba,Japan.Purpose: Purpose: SOD-1 knock out mouse has been reported to be amodel for age related dry eye disease. We investigated the alterationsin the tear function and conjunctival ocular surface epithelialdifferentiation in the Sod1-/- in comparison to the wild type mice.Methods: Methods: Ten eyes of 5 Sod1-/- male mice withC57BL/background and 10 eyes of 5 C57BL6 strain wild-type malemice were examined at 10 and 50 weeks in this study. Tear filmstability and corneal epithelial damage was evaluated by fluoresceinand Rose Bengal stainings. Anterior segment photography wascarried out at 10 to 50 weeks. Aqueous tear quantity was measuredwith phenol-red-impregnated cotton threads without anesthesia.Animals were sacrificed and the whole globe specimens underwentPAS and SPDEF(SAM pointed domain containing ets transcriptionfactor) immunohistichemistry staining. Quantitative Real Time-PCRfor conjunctival muc 5AC mRNA and SPDEF expression was alsoperformed. All studies were performed in accordance with the <strong>ARVO</strong>Statement for the Use of Animals in Ophthalmic and VisionResearch. Statistical analysis was performed by using t test andANOVA. A p value
<strong>ARVO</strong> 2013 Annual Meeting Abstracts by Scientific Section/Group - <strong>Cornea</strong>Commercial Relationships: MURAT DOGRU, OtsukaPharmaceuticals (F); Takashi Kojima, None; Taeko Nagata, None;Ayako Igarashi, None; Kazunari Higa, None; Yoshiyuki Satake,None; Seika Shimazaki, None; Shimizu Takahiko, None; KazuoTsubota, AcuFocus, Inc (C), Allergan (F), Bausch Lomb Surgical(C), Functional visual acuity meter (P), JiNS (P), Kissei (F), Kowa(F), Santen, Inc. (F), Otsuka (F), Pfizer (C), Thea (C), Echo Denki(P), Nidek (F), Ophtecs (F), Wakasa Seikatsu (F), CEPT Company(P); Jun Shimazaki, Santen Pharmaceutical Co. (F), OtsukaPharmaceutical Co. (F), Abott Medical Optics (F)Support: Otsuka PharmaceuticalsProgram Number: 4315 Poster Board Number: C0053Presentation Time: 8:30 AM - 10:15 AML-carnitine, Erythritol and Betaine Suppress the Production andActivity of Matrix Metalloproteinases in Primary Human<strong>Cornea</strong>l Epithelial Cells Exposed to Hyperosmotic StressRuzhi Deng 1, 2 , Zhitao Su 1, 2 , Jing Lin 1 , Xia Hua 1 , De-Quan Li 1 ,Stephen C. Pflugfelder 1 . 1 Department of Ophthalmology, BaylorCollege of Medicine, Houston, TX; 2 Optometry and Ophthalmology,Wenzhou Medical College, Wenzhou, China.Purpose: Hyperosmolarity has been recognized to be a proinflammatorystress in the pathogenesis of dry eye disease. This studyinvestigated the suppressive effect of osmoprotectants (L-carnitine,erythritol and betaine) on the production and activity of matrixmetalloproteinases (MMPs) in primary human corneal epithelial cells(HCECs) exposed to hyperosmotic stress.Methods: Primary HCECs were established from fresh donor limbaltissue explants. The cultures in iso-osmolar medium (312 mOsM)were switched to hyperosmotic media (400-500 mOsM) by adding50-90 mM NaCl, with or without prior incubation with differentconcentrations (2, 10 or 20mM) of L-carnitine, erythritol or betaine.The mRNA expression of MMPs by HCECs treated for 4 hours wasdetermined by reverse transcription and quantitative real time PCR.Their protein production and activity in the conditioned media fromcultures treated for 24-48 hours were evaluated by zymography,immunofluorescent staining, ELISA and activity assays.Results: Hyperosmotic stress (400, 450 or 500 mOsM) significantlystimulated the mRNA expression of collagenase MMP13 (3.1 to 7.5fold), gelatinase MMP9 (1.7 to 2.5 fold), stromelysin MMP3 (2.2 to4.1 fold) and matrilysin MMP7 (2.3 to 4.5 fold), mostly in anosmolarity dependent fashion. Interestingly, the stimulatedexpression of these MMPs was significantly, but differentiallysuppressed by L-carnitine, erythritol or betaine. L-carnitine appearedto have the greatest inhibitory effects, and down-regulated 52-78%,respectively, of the stimulated mRNA levels of MMP13 (down from7.0 to 3.1 fold), MMP9 (2.5 to 1.2 fold), MMP3 (4.1 to 0.9 fold), andMMP7 (4.5 to 1.5 fold) by HCECs exposed to 450 mOsM. Thestimulated production and activity of these MMPs by hyperosmoticstress and the suppressive effects of L-carnitine, erythritol andbetaine were further confirmed at protein levels by gelatin and caseingel zymography, immunofluorescent staining, ELISA and/or activityassays, respectively.Conclusions: Our findings demonstrate that hyperosmotic stressstimulates the expression, production and activity of MMPs inHCECs. L-carnitine, erythritol and betaine serve as osmoprotectantsthat suppress the production and activity of MMPs in HCECsexposed to hyperosmotic stress. L-carnitine shows the best inhibitoryeffect among the three.Commercial Relationships: Ruzhi Deng, None; Zhitao Su, None;Jing Lin, None; Xia Hua, None; De-Quan Li, None; Stephen C.Pflugfelder, Allergan (C), Glaxo Smith Kline (C), Bausch and Lomb(C), Baylor College of Medicine (P)Support: NIH Grants EY11915(SCP) and Core Grant for VisionResarch EY002520., Allergan Inc., Research to Prevent Blindness.,Oshman Foundation,. William Stamps Farish Fund.Program Number: 4316 Poster Board Number: C0054Presentation Time: 8:30 AM - 10:15 AMSuppressive effects of 17β-estradiol on immortalized humanmeibomian gland epithelial cellsWendy R. Kam, David A. Sullivan. Schepens Eye Research Institute,Massachusetts Eye and Ear, Harvard Medical School, Boston, MA.Purpose: Previous studies have shown that 17β-estradiol (E 2 )significantly decreases adenylate cyclase activity in bone cells,thereby attenuating the cyclic AMP response to stimulatory factors(e.g. the secretagogue forskolin). It is possible that this inhibitoryeffect on signal transduction represents one mechanism by whichestrogens suppress sebaceous gland epithelial cell function. If so,such an E 2 influence on the meibomian gland, which is a largesebaceous gland, could account for the increased incidence of dry eyedisease in women taking estrogen replacement therapy. Our objectivewas to determine whether E 2 attenuates secretagogue-induced cAMPaccumulation in immortalized human meibomian gland epithelialcells (iHMGEC). As part of these studies, we also evaluated whetherE 2 modulates iHMGEC proliferation.Methods: Immortalized human meibomian gland epithelial cellswere cultured in medium free of serum and phenol red prior totreatment. For cAMP analysis, cells were treated with E 2 (100 pM),forskolin (100 µM), the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX; 1 mM), or buffer for 10 minutes prior toquantification of intracellular cAMP with a colorimetric enzymelinkedimmunoassay. For proliferation studies, cells exposed to E 2 orbuffer for 1, 3, and 5 days were counted with a hemocytometer.Results: Estrogen treatment caused a significant decrease insecretagogue-induced cAMP accumulation in iHMGEC. Thishormonal effect was observed after cellular exposure to eitherforskolin or IBMX. In contrast, in the absence of E 2 , forskolin andIBMX elicited rapid intracellular cAMP accumulation. Treatment ofiHMGEC with E 2 for 5 days caused a slight but significant decreasein proliferation.Conclusions: Our research demonstrates that E 2 may suppress bothcAMP signaling in, and the proliferation of, iHMGEC. Themechanisms underlying these estrogen effects, as well as theirpossible role in promoting dry eye, remain to be clarified.Commercial Relationships: Wendy R. Kam, None; David A.Sullivan, Forest Research Institute (C), Horus Pharma (R), TearLab(S), Lubris (I), Santen (R)Support: NIH grant EY05612 and the Margaret S. Sinon Scholar inOcular Surface Research fundProgram Number: 4317 Poster Board Number: C0055Presentation Time: 8:30 AM - 10:15 AMImpact of azithromycin on lipid accumulation in immortalizedhuman meibomian gland epithelial cellsYang Liu, Wendy R. Kam, Juan Ding, David A. Sullivan. SchepensEye Research Institute, Massachusetts Eye and Ear, Harvard MedicalSchool, Boston, MA.Purpose: Meibomian gland dysfunction(MGD) is believed to be theleading cause of dry eye disease(DED) in the world, and afflicts tensof millions Americans. Perhaps the most common MGD treatment inthe USA is the off-label use of topical azithromycin.The efficacy ofthis macrolide antibiotic has been ascribed to its anti-inflammatoryand antibacterial actions. However, the mechanism by whichazithromycin acts on the meibomian gland is unknown. Wehypothesize that azithromycin promotes lipid accumulation in human©2013, Copyright by the Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Go to iovs.org to access the version of record. For permissionto reproduce any abstract, contact the <strong>ARVO</strong> Office at arvo@arvo.org.
- Page 2 and 3:
ARVO 2013 Annual Meeting Abstracts
- Page 4 and 5:
ARVO 2013 Annual Meeting Abstracts
- Page 6 and 7:
ARVO 2013 Annual Meeting Abstracts
- Page 8 and 9:
ARVO 2013 Annual Meeting Abstracts
- Page 10:
ARVO 2013 Annual Meeting Abstracts
- Page 13 and 14:
ARVO 2013 Annual Meeting Abstracts
- Page 16 and 17:
ARVO 2013 Annual Meeting Abstracts
- Page 18 and 19:
ARVO 2013 Annual Meeting Abstracts
- Page 20 and 21:
ARVO 2013 Annual Meeting Abstracts
- Page 22 and 23:
ARVO 2013 Annual Meeting Abstracts
- Page 24 and 25:
ARVO 2013 Annual Meeting Abstracts
- Page 26 and 27:
ARVO 2013 Annual Meeting Abstracts
- Page 28 and 29:
ARVO 2013 Annual Meeting Abstracts
- Page 30 and 31:
ARVO 2013 Annual Meeting Abstracts
- Page 32 and 33:
ARVO 2013 Annual Meeting Abstracts
- Page 34 and 35:
ARVO 2013 Annual Meeting Abstracts
- Page 36 and 37:
ARVO 2013 Annual Meeting Abstracts
- Page 38 and 39:
ARVO 2013 Annual Meeting Abstracts
- Page 40 and 41:
ARVO 2013 Annual Meeting Abstracts
- Page 42 and 43:
ARVO 2013 Annual Meeting Abstracts
- Page 44 and 45:
ARVO 2013 Annual Meeting Abstracts
- Page 46 and 47:
ARVO 2013 Annual Meeting Abstracts
- Page 48 and 49:
ARVO 2013 Annual Meeting Abstracts
- Page 50 and 51:
ARVO 2013 Annual Meeting Abstracts
- Page 52 and 53:
ARVO 2013 Annual Meeting Abstracts
- Page 54 and 55:
ARVO 2013 Annual Meeting Abstracts
- Page 56 and 57:
ARVO 2013 Annual Meeting Abstracts
- Page 58 and 59:
ARVO 2013 Annual Meeting Abstracts
- Page 60 and 61:
ARVO 2013 Annual Meeting Abstracts
- Page 62 and 63:
ARVO 2013 Annual Meeting Abstracts
- Page 64 and 65:
ARVO 2013 Annual Meeting Abstracts
- Page 66 and 67:
ARVO 2013 Annual Meeting Abstracts
- Page 68 and 69:
ARVO 2013 Annual Meeting Abstracts
- Page 70 and 71:
ARVO 2013 Annual Meeting Abstracts
- Page 72 and 73:
ARVO 2013 Annual Meeting Abstracts
- Page 74 and 75:
ARVO 2013 Annual Meeting Abstracts
- Page 76 and 77:
ARVO 2013 Annual Meeting Abstracts
- Page 78 and 79:
ARVO 2013 Annual Meeting Abstracts
- Page 80 and 81:
ARVO 2013 Annual Meeting Abstracts
- Page 82 and 83:
ARVO 2013 Annual Meeting Abstracts
- Page 84 and 85:
ARVO 2013 Annual Meeting Abstracts
- Page 86 and 87:
ARVO 2013 Annual Meeting Abstracts
- Page 88 and 89:
ARVO 2013 Annual Meeting Abstracts
- Page 90 and 91:
ARVO 2013 Annual Meeting Abstracts
- Page 92 and 93:
ARVO 2013 Annual Meeting Abstracts
- Page 94 and 95:
ARVO 2013 Annual Meeting Abstracts
- Page 96 and 97:
ARVO 2013 Annual Meeting Abstracts
- Page 98 and 99:
ARVO 2013 Annual Meeting Abstracts
- Page 100 and 101:
ARVO 2013 Annual Meeting Abstracts
- Page 102 and 103:
ARVO 2013 Annual Meeting Abstracts
- Page 104 and 105:
ARVO 2013 Annual Meeting Abstracts
- Page 106 and 107:
ARVO 2013 Annual Meeting Abstracts
- Page 108 and 109:
ARVO 2013 Annual Meeting Abstracts
- Page 110 and 111:
ARVO 2013 Annual Meeting Abstracts
- Page 112 and 113:
ARVO 2013 Annual Meeting Abstracts
- Page 114 and 115:
ARVO 2013 Annual Meeting Abstracts
- Page 116 and 117:
ARVO 2013 Annual Meeting Abstracts
- Page 118 and 119:
ARVO 2013 Annual Meeting Abstracts
- Page 120 and 121:
ARVO 2013 Annual Meeting Abstracts
- Page 122 and 123:
ARVO 2013 Annual Meeting Abstracts
- Page 124 and 125:
ARVO 2013 Annual Meeting Abstracts
- Page 126 and 127:
ARVO 2013 Annual Meeting Abstracts
- Page 128 and 129:
ARVO 2013 Annual Meeting Abstracts
- Page 130 and 131:
ARVO 2013 Annual Meeting Abstracts
- Page 132 and 133:
ARVO 2013 Annual Meeting Abstracts
- Page 134 and 135:
ARVO 2013 Annual Meeting Abstracts
- Page 136 and 137:
ARVO 2013 Annual Meeting Abstracts
- Page 138 and 139:
ARVO 2013 Annual Meeting Abstracts
- Page 140 and 141:
ARVO 2013 Annual Meeting Abstracts
- Page 142 and 143:
ARVO 2013 Annual Meeting Abstracts
- Page 144 and 145:
ARVO 2013 Annual Meeting Abstracts
- Page 146 and 147:
ARVO 2013 Annual Meeting Abstracts
- Page 148 and 149:
ARVO 2013 Annual Meeting Abstracts
- Page 150 and 151:
ARVO 2013 Annual Meeting Abstracts
- Page 152 and 153:
ARVO 2013 Annual Meeting Abstracts
- Page 154 and 155:
ARVO 2013 Annual Meeting Abstracts
- Page 156 and 157:
ARVO 2013 Annual Meeting Abstracts
- Page 158 and 159:
ARVO 2013 Annual Meeting Abstracts
- Page 160 and 161:
ARVO 2013 Annual Meeting Abstracts
- Page 162 and 163:
ARVO 2013 Annual Meeting Abstracts
- Page 164 and 165:
ARVO 2013 Annual Meeting Abstracts
- Page 166 and 167:
ARVO 2013 Annual Meeting Abstracts
- Page 168 and 169:
ARVO 2013 Annual Meeting Abstracts
- Page 170 and 171:
ARVO 2013 Annual Meeting Abstracts
- Page 172 and 173:
ARVO 2013 Annual Meeting Abstracts
- Page 174 and 175:
ARVO 2013 Annual Meeting Abstracts
- Page 176 and 177:
ARVO 2013 Annual Meeting Abstracts
- Page 178 and 179:
ARVO 2013 Annual Meeting Abstracts
- Page 180 and 181:
ARVO 2013 Annual Meeting Abstracts
- Page 182 and 183:
ARVO 2013 Annual Meeting Abstracts
- Page 184 and 185:
ARVO 2013 Annual Meeting Abstracts
- Page 186 and 187:
ARVO 2013 Annual Meeting Abstracts
- Page 188 and 189:
ARVO 2013 Annual Meeting Abstracts
- Page 190 and 191:
ARVO 2013 Annual Meeting Abstracts
- Page 192 and 193:
ARVO 2013 Annual Meeting Abstracts
- Page 194 and 195:
ARVO 2013 Annual Meeting Abstracts
- Page 196 and 197:
ARVO 2013 Annual Meeting Abstracts
- Page 198 and 199:
ARVO 2013 Annual Meeting Abstracts
- Page 200 and 201:
ARVO 2013 Annual Meeting Abstracts
- Page 202 and 203:
ARVO 2013 Annual Meeting Abstracts
- Page 204 and 205:
ARVO 2013 Annual Meeting Abstracts
- Page 206 and 207:
ARVO 2013 Annual Meeting Abstracts
- Page 208 and 209:
ARVO 2013 Annual Meeting Abstracts
- Page 210 and 211:
ARVO 2013 Annual Meeting Abstracts
- Page 212 and 213: ARVO 2013 Annual Meeting Abstracts
- Page 214 and 215: ARVO 2013 Annual Meeting Abstracts
- Page 216 and 217: ARVO 2013 Annual Meeting Abstracts
- Page 218 and 219: ARVO 2013 Annual Meeting Abstracts
- Page 220 and 221: ARVO 2013 Annual Meeting Abstracts
- Page 222 and 223: ARVO 2013 Annual Meeting Abstracts
- Page 224 and 225: ARVO 2013 Annual Meeting Abstracts
- Page 226 and 227: ARVO 2013 Annual Meeting Abstracts
- Page 228 and 229: ARVO 2013 Annual Meeting Abstracts
- Page 230 and 231: ARVO 2013 Annual Meeting Abstracts
- Page 232 and 233: ARVO 2013 Annual Meeting Abstracts
- Page 234 and 235: ARVO 2013 Annual Meeting Abstracts
- Page 236 and 237: ARVO 2013 Annual Meeting Abstracts
- Page 238 and 239: ARVO 2013 Annual Meeting Abstracts
- Page 240 and 241: ARVO 2013 Annual Meeting Abstracts
- Page 242 and 243: ARVO 2013 Annual Meeting Abstracts
- Page 244 and 245: ARVO 2013 Annual Meeting Abstracts
- Page 246 and 247: ARVO 2013 Annual Meeting Abstracts
- Page 248 and 249: ARVO 2013 Annual Meeting Abstracts
- Page 250 and 251: ARVO 2013 Annual Meeting Abstracts
- Page 252 and 253: ARVO 2013 Annual Meeting Abstracts
- Page 254 and 255: ARVO 2013 Annual Meeting Abstracts
- Page 256 and 257: ARVO 2013 Annual Meeting Abstracts
- Page 258 and 259: ARVO 2013 Annual Meeting Abstracts
- Page 260 and 261: ARVO 2013 Annual Meeting Abstracts
- Page 264 and 265: ARVO 2013 Annual Meeting Abstracts
- Page 266 and 267: ARVO 2013 Annual Meeting Abstracts
- Page 268 and 269: ARVO 2013 Annual Meeting Abstracts
- Page 270 and 271: ARVO 2013 Annual Meeting Abstracts
- Page 272 and 273: ARVO 2013 Annual Meeting Abstracts
- Page 274 and 275: ARVO 2013 Annual Meeting Abstracts
- Page 276 and 277: ARVO 2013 Annual Meeting Abstracts
- Page 278 and 279: ARVO 2013 Annual Meeting Abstracts
- Page 280 and 281: ARVO 2013 Annual Meeting Abstracts
- Page 282 and 283: ARVO 2013 Annual Meeting Abstracts
- Page 284 and 285: ARVO 2013 Annual Meeting Abstracts
- Page 286 and 287: ARVO 2013 Annual Meeting Abstracts
- Page 288 and 289: ARVO 2013 Annual Meeting Abstracts
- Page 290 and 291: ARVO 2013 Annual Meeting Abstracts
- Page 292 and 293: ARVO 2013 Annual Meeting Abstracts
- Page 294 and 295: ARVO 2013 Annual Meeting Abstracts
- Page 296 and 297: ARVO 2013 Annual Meeting Abstracts
- Page 298 and 299: ARVO 2013 Annual Meeting Abstracts
- Page 300 and 301: ARVO 2013 Annual Meeting Abstracts
- Page 302 and 303: ARVO 2013 Annual Meeting Abstracts
- Page 304 and 305: ARVO 2013 Annual Meeting Abstracts
- Page 306 and 307: ARVO 2013 Annual Meeting Abstracts
- Page 308 and 309: ARVO 2013 Annual Meeting Abstracts
- Page 310 and 311: ARVO 2013 Annual Meeting Abstracts
- Page 312 and 313:
ARVO 2013 Annual Meeting Abstracts
- Page 314 and 315:
ARVO 2013 Annual Meeting Abstracts
- Page 316 and 317:
ARVO 2013 Annual Meeting Abstracts
- Page 318 and 319:
ARVO 2013 Annual Meeting Abstracts
- Page 320 and 321:
ARVO 2013 Annual Meeting Abstracts
- Page 322 and 323:
ARVO 2013 Annual Meeting Abstracts
- Page 324 and 325:
ARVO 2013 Annual Meeting Abstracts
- Page 326 and 327:
ARVO 2013 Annual Meeting Abstracts
- Page 328 and 329:
ARVO 2013 Annual Meeting Abstracts
- Page 330 and 331:
ARVO 2013 Annual Meeting Abstracts
- Page 332 and 333:
ARVO 2013 Annual Meeting Abstracts
- Page 334 and 335:
ARVO 2013 Annual Meeting Abstracts
- Page 336 and 337:
ARVO 2013 Annual Meeting Abstracts
- Page 338 and 339:
ARVO 2013 Annual Meeting Abstracts
- Page 340 and 341:
ARVO 2013 Annual Meeting Abstracts
- Page 342 and 343:
ARVO 2013 Annual Meeting Abstracts
- Page 344 and 345:
ARVO 2013 Annual Meeting Abstracts
- Page 346 and 347:
ARVO 2013 Annual Meeting Abstracts
- Page 348 and 349:
ARVO 2013 Annual Meeting Abstracts
- Page 350 and 351:
ARVO 2013 Annual Meeting Abstracts
- Page 352 and 353:
ARVO 2013 Annual Meeting Abstracts
- Page 354 and 355:
ARVO 2013 Annual Meeting Abstracts
- Page 356 and 357:
ARVO 2013 Annual Meeting Abstracts
- Page 358 and 359:
ARVO 2013 Annual Meeting Abstracts
- Page 360 and 361:
ARVO 2013 Annual Meeting Abstracts
- Page 362 and 363:
ARVO 2013 Annual Meeting Abstracts
- Page 364 and 365:
ARVO 2013 Annual Meeting Abstracts
- Page 366 and 367:
ARVO 2013 Annual Meeting Abstracts
- Page 368 and 369:
ARVO 2013 Annual Meeting Abstracts
- Page 370 and 371:
ARVO 2013 Annual Meeting Abstracts
- Page 372 and 373:
ARVO 2013 Annual Meeting Abstracts
- Page 374 and 375:
ARVO 2013 Annual Meeting Abstracts
- Page 376 and 377:
ARVO 2013 Annual Meeting Abstracts
- Page 378 and 379:
ARVO 2013 Annual Meeting Abstracts
- Page 380 and 381:
ARVO 2013 Annual Meeting Abstracts
- Page 382 and 383:
ARVO 2013 Annual Meeting Abstracts